Protagonist Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 112
- Market Cap
- $2.4B
- Introduction
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Clinical Trials
45
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (44 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Protagonist Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06033586
- Locations
- 🇺🇸
Pontchartrain Cancer Care, Covington, Louisiana, United States
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Protagonist Therapeutics, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT05210790
- Locations
- 🇺🇸
Infirmary Cancer Care, Mobile, Alabama, United States
🇺🇸Palo Verde Hematology-Oncology, Glendale, Arizona, United States
🇺🇸City of Hope Medical Center, Duarte, Duarte, California, United States
Pharmacokinetics of PN-232 in Healthy Volunteers
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Protagonist Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04819620
- Locations
- 🇦🇺
Protagonist Clinical Site, Adelaide, South Australia, Australia
🇦🇺Protagonist Study Site, Nedlands, Western Australia, Australia
PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Protagonist Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04767802
- Locations
- 🇰🇷
Gachon University Medical Center, Incheon, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Seoul St. Mary's Catholic University Hospital, Seoul, Korea, Republic of
Pharmacokinetics of PN-235 in Healthy Volunteers
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Protagonist Therapeutics, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT04621630
- Locations
- 🇦🇺
Nucleus Network Melbourne Clinic, Melbourne, Australia
- Prev
- 1
- 2
- 3
- Next
News
Protagonist Therapeutics Advances PN-477 Triple Agonist for Obesity Treatment, Targeting Same Mechanism as Eli Lilly's Retatrutide
Protagonist Therapeutics has selected PN-477, a novel triple agonist peptide targeting GLP-1, GIP, and GCG receptors, as a development candidate for obesity treatment with both oral and injectable formulations.
Protagonist's Icotrokinra Shows Promising Results in Ulcerative Colitis and Psoriasis Trials
Protagonist Therapeutics and Johnson & Johnson's oral peptide icotrokinra achieved 63.5% clinical response rate in ulcerative colitis patients at Week 12, significantly outperforming placebo in the Phase 2b ANTHEM-UC study.
Protagonist and Takeda's Rusfertide Shows Positive Phase 3 Results in Polycythemia Vera
Rusfertide, developed by Protagonist Therapeutics and Takeda, achieved significant success in Phase 3 trial for polycythemia vera patients, demonstrating superior blood count control.
Rusfertide Shows Promising Results in Phase 3 Trial for Polycythemia Vera Treatment
Protagonist Therapeutics' experimental drug rusfertide achieved primary efficacy endpoints in Phase 3 trial for polycythemia vera, demonstrating successful stabilization of red blood cells.
Protagonist Therapeutics Reports Strong Financial Growth with Key Clinical Milestones Ahead in Q1 2025
Protagonist Therapeutics secured a significant $165 million milestone payment for icotrokinra in Q4 2024, strengthening their financial position with total cash reserves of $559.2 million.
Protagonist Therapeutics' Rusfertide Shows Promise in Polycythemia Vera Treatment
Protagonist Therapeutics' rusfertide demonstrates durable hematocrit control in Phase 3 trials for polycythemia vera, reducing the need for phlebotomy.
Icotrokinra Shows Promise in Phase 3 Trials for Plaque Psoriasis
Icotrokinra, an oral peptide targeting the IL-23 receptor, met primary endpoints in two Phase 3 trials for moderate-to-severe plaque psoriasis.
Protagonist Therapeutics' Oral Icotrokinra Achieves Positive Phase 3 Results for Plaque Psoriasis
Protagonist Therapeutics' icotrokinra, an oral peptide drug, demonstrated significant skin clearance in Phase 3 trials for moderate-to-severe plaque psoriasis.
Icotrokinra Shows Promise as Oral Treatment for Plaque Psoriasis in Phase 3 Trial
Icotrokinra, an oral peptide drug blocking the IL-23 receptor, demonstrated significant clearance of psoriatic plaques in a Phase 3 trial.
JNJ-2113 Demonstrates Significant Skin Clearance in Phase 3 Psoriasis Trials
Phase 3 trials ICONIC-LEAD and ICONIC-TOTAL showed JNJ-2113 significantly improved skin clearance in moderate-to-severe plaque psoriasis patients compared to placebo.